Memantine loaded micro/nanoscale magnetic motors for the treatment of Alzheimer's Disease

IF 4.5 3区 医学 Q1 PHARMACOLOGY & PHARMACY
Gizem Tezel Temel , Elif Öztürk , Sıla Ulutürk , Süleyman Can Öztürk , Tuba Reçber , Selin Seda Timur , Emirhan Nemutlu , Filiz Kuralay , Güneş Esendağlı , R. Neslihan Gürsoy , Levent Öner , Hakan Ceylan , Hakan Eroğlu
{"title":"Memantine loaded micro/nanoscale magnetic motors for the treatment of Alzheimer's Disease","authors":"Gizem Tezel Temel ,&nbsp;Elif Öztürk ,&nbsp;Sıla Ulutürk ,&nbsp;Süleyman Can Öztürk ,&nbsp;Tuba Reçber ,&nbsp;Selin Seda Timur ,&nbsp;Emirhan Nemutlu ,&nbsp;Filiz Kuralay ,&nbsp;Güneş Esendağlı ,&nbsp;R. Neslihan Gürsoy ,&nbsp;Levent Öner ,&nbsp;Hakan Ceylan ,&nbsp;Hakan Eroğlu","doi":"10.1016/j.jddst.2025.107043","DOIUrl":null,"url":null,"abstract":"<div><div>Micro/nanomotors (MNM) are self-propelled devices operating at the nano or microscale, offering significant potential for applications such as drug delivery, cell manipulation, bio-imaging, diagnostics, and environmental remediation. In this study, we report for the first time the development of novel, magnetically actuated MNMs loaded with Memantine (Mem) toward the treatment of Alzheimer's Disease (AD). AD, a neurodegenerative disease with no cure, presents a significant challenge due to its increasing prevalence. This research aimed to design a targeted drug delivery system using Mem, a common AD treatment, loaded onto magnetically maneuverable MNMs. The fabricated Mem-loaded MNMs were thoroughly characterized in terms of morphology, particle size, drug loading efficiency, magnetic actuation and in vitro drug release kinetics. The final formulation exhibited a drug loading efficiency of 14.06 ± 5.2 % and achieved 95 ± 2.4 % drug release within 72 h. The average velocity of the Mem loaded magnetically propelled MNMs was determined as 16.3 ± 2.3 μm/s. Cytotoxicity assessments in SH-SY5Y cells confirmed the non-toxicity of the MNM formulation (77.08 ± 2.5 % viability at 48 h), while efficacy studies demonstrated significant BACE1 inhibition and TrkB upregulation, with superior blood brain barrier (BBB) model suppression versus Mem solution, indicating potential for enhanced BBB drug delivery and therapeutic benefit. Metabolomic analysis corroborated these findings, showing alterations in glutathione, asparagine, phosphatidylcholine, and phosphatidylinositol levels, consistent with AD-related metabolic changes. <em>In vivo</em> biodistribution in Balb-C mice showed significant MNM brain accumulation within 30 min. Altogether, this study suggests that magnetically actuated, Mem-loaded MNMs represent a promising strategy for leveraging efforts in managing Alzheimer's Disease through enhanced, site-specific drug delivery approaches.</div></div>","PeriodicalId":15600,"journal":{"name":"Journal of Drug Delivery Science and Technology","volume":"110 ","pages":"Article 107043"},"PeriodicalIF":4.5000,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drug Delivery Science and Technology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1773224725004460","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Micro/nanomotors (MNM) are self-propelled devices operating at the nano or microscale, offering significant potential for applications such as drug delivery, cell manipulation, bio-imaging, diagnostics, and environmental remediation. In this study, we report for the first time the development of novel, magnetically actuated MNMs loaded with Memantine (Mem) toward the treatment of Alzheimer's Disease (AD). AD, a neurodegenerative disease with no cure, presents a significant challenge due to its increasing prevalence. This research aimed to design a targeted drug delivery system using Mem, a common AD treatment, loaded onto magnetically maneuverable MNMs. The fabricated Mem-loaded MNMs were thoroughly characterized in terms of morphology, particle size, drug loading efficiency, magnetic actuation and in vitro drug release kinetics. The final formulation exhibited a drug loading efficiency of 14.06 ± 5.2 % and achieved 95 ± 2.4 % drug release within 72 h. The average velocity of the Mem loaded magnetically propelled MNMs was determined as 16.3 ± 2.3 μm/s. Cytotoxicity assessments in SH-SY5Y cells confirmed the non-toxicity of the MNM formulation (77.08 ± 2.5 % viability at 48 h), while efficacy studies demonstrated significant BACE1 inhibition and TrkB upregulation, with superior blood brain barrier (BBB) model suppression versus Mem solution, indicating potential for enhanced BBB drug delivery and therapeutic benefit. Metabolomic analysis corroborated these findings, showing alterations in glutathione, asparagine, phosphatidylcholine, and phosphatidylinositol levels, consistent with AD-related metabolic changes. In vivo biodistribution in Balb-C mice showed significant MNM brain accumulation within 30 min. Altogether, this study suggests that magnetically actuated, Mem-loaded MNMs represent a promising strategy for leveraging efforts in managing Alzheimer's Disease through enhanced, site-specific drug delivery approaches.
用于治疗阿尔茨海默病的美金刚负载微/纳米级磁马达
微/纳米马达(MNM)是在纳米或微尺度上运行的自推进装置,在药物输送、细胞操作、生物成像、诊断和环境修复等应用方面具有巨大的潜力。在这项研究中,我们首次报道了一种新型的、磁驱动的装载美金刚胺(Memantine, Mem)的mnm用于治疗阿尔茨海默病(AD)的进展。阿尔茨海默病是一种无法治愈的神经退行性疾病,由于其发病率不断上升,因此提出了重大挑战。本研究旨在设计一种靶向药物递送系统,将Mem(一种常见的阿尔茨海默病治疗药物)装载到磁性可操作的MNMs上。从形貌、粒径、载药效率、磁致动和体外药物释放动力学等方面对所制备的负载mems的MNMs进行了表征。最终配方的载药效率为14.06±5.2%,72 h内释药率为95±2.4%,磁推进纳米颗粒的平均速度为16.3±2.3 μm/s。SH-SY5Y细胞的细胞毒性评估证实了MNM配方的无毒性(48 h存活率为77.08±2.5%),而功效研究显示了显著的BACE1抑制和TrkB上调,与Mem溶液相比,具有更好的血脑屏障(BBB)模型抑制,表明可能增强BBB药物传递和治疗益处。代谢组学分析证实了这些发现,显示谷胱甘肽、天冬酰胺、磷脂酰胆碱和磷脂酰肌醇水平的变化与ad相关的代谢变化一致。Balb-C小鼠的体内生物分布显示,MNM在30分钟内在大脑中显著积累。总之,本研究表明,磁驱动、装载MNM的MNMs代表了一种有前途的策略,可以通过增强的、特定部位的给药方法来管理阿尔茨海默病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.00
自引率
8.00%
发文量
879
审稿时长
94 days
期刊介绍: The Journal of Drug Delivery Science and Technology is an international journal devoted to drug delivery and pharmaceutical technology. The journal covers all innovative aspects of all pharmaceutical dosage forms and the most advanced research on controlled release, bioavailability and drug absorption, nanomedicines, gene delivery, tissue engineering, etc. Hot topics, related to manufacturing processes and quality control, are also welcomed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信